In the era of COVID-19 an immense number of people came together to do what they could do help save lives. Amongst those were the orthodox Jewish community in NY (plasma and mAbs) and the Israeli medical community (vaccine data). Much gratitude is owed them.
The Times has disgraced themselves maliciously going after one of the very few truly peaceful and humble communities.
Stunning and disgusting revelations looking into their recent reporting on Hasidic Jews. https://t.co/CFWTEY7S4l
Caring for people with long-haul #COVID19 is helping to bring legitimacy to conditions like chronic fatigue syndrome and fibromyalgia, which are sometimes wrongly characterized as being “all in the head.” Learn more from @DrMJoyner. @MayoClinic https://t.co/BhvrNY9VJN
For those with extra covid concerns.
The Orthodox Jewish community of Lakewood NJ was one of the safest places to live in this past year. Their ability to save lives during covid-19 has been amazing.
Here I am quoted extensively on why I disagree with the @WHO recommendation on convalescent plasma. I stand by my comment that I believe that @WHO erred in their statement. Hope they reconsider in light of omicron, which can defeat monoclonal antibodies.
https://t.co/y8HTGCJ7vM
FDA authorizes long-acting pre-exposure monoclonal antibodies for immunocompromised/transplant patients!! Game-changer!! (that said, vaccination is still important for everyone, including immunocompromised) Spread the word!
Our data comparing subQ to IV casirivimab and imdevimab are now available @medrxivpreprint
Better put, our story of how we solved a health system capacity management crisis is online for all to review and comment :)
https://t.co/rHLJ69wkK2 1/n
@UPMCnews@IDPittStop@PittTweet
Honored (and terrified) to be included in the Jewish Federation of Ocean County's local Heroes Against Hate for their upcoming Community of Caring event for my work with @one_county
Learn more about this event:
https://t.co/WJgjbLuLqA
1-year MATRx anniversary
11/19/2020: first patient infused with #monoclonalantibody
11/19/2021: over 17,000 patients have received the therapy in our program.
We thank MATRx members for their dedication in screening, consenting and infusing these mAbs to high-risk patients!